AlzeCure Pharma AB (publ)
SSE:ALZCUR.ST
2.49 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0.883 |
| Cost of Revenue
| 0.476 | 0.57 | 0.576 | 0.495 | 44.789 | 0.104 | 0.008 |
| Gross Profit
| -0.476 | -0.57 | -0.576 | -0.495 | -44.789 | -0.104 | 0.875 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0.991 |
| Reseach & Development Expenses
| 27.707 | 46.183 | 66.715 | 62.356 | 44.789 | 36.828 | 10.973 |
| General & Administrative Expenses
| 10.598 | 10.168 | 11.265 | 9.375 | 6.035 | 32.495 | 0.733 |
| Selling & Marketing Expenses
| 10.587 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 10.598 | 10.168 | 11.265 | 9.375 | 6.035 | 32.495 | 0.733 |
| Other Expenses
| -0.043 | 0.218 | 0.163 | 0.291 | 0.181 | 3.644 | -0.939 |
| Operating Expenses
| 38.262 | 56.569 | 78.143 | 72.022 | 51.005 | 36.139 | 10.767 |
| Operating Income
| -38.262 | -56.442 | -77.926 | -71.579 | -50.908 | -35.893 | -10.767 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -12.188 |
| Total Other Income Expenses Net
| 1.095 | 0.203 | 0.145 | 0.213 | 0.05 | 0.154 | -0.055 |
| Income Before Tax
| -37.167 | -56.239 | -77.781 | -71.366 | -50.858 | -35.985 | -10.822 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -12.251 |
| Income Tax Expense
| -0.082 | -0.203 | 0.001 | 0.001 | 0.149 | 0.246 | 0 |
| Net Income
| -37.167 | -56.036 | -77.782 | -71.367 | -51.007 | -35.985 | -10.822 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -12.251 |
| EPS
| -0.6 | -1.17 | -1.98 | -1.82 | -1.3 | -1.52 | -0.57 |
| EPS Diluted
| -0.6 | -1.17 | -1.98 | -1.82 | -1.3 | -1.52 | -0.57 |
| EBITDA
| -37.868 | -55.665 | -77.204 | -70.87 | -50.419 | -35.789 | -10.759 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -12.179 |